Known Upcoming events, incl. ASCO May30-June1(2 Abstracts)
May21: NYAS: Emerging Approaches to Cancer Immunotherapy, NYC http://tinyurl.com/lfdoksl …3:10pm: Dr. Rolf Brekken, “Lifting the Veil of Immune Suppression and Inducing Immune Activation through Antibody-mediated Blockade of Phosphatidylserine Signaling”
May29-Jun2: ASCO Annual Meeting 2015, Chicago http://am.asco.org - see: http://tinyurl.com/lfdoksl ...May30 #3060/S.Altiok(Moffitt): “Activation of CD8+ Tumor Infiltrating Lymphocytes by Bavituximab in a 3D ex vivo System of Lung Cancer Patients” ...Jun1 #4109/Adam Yopp(UTSW): “A Phase I/II Study of Bavituximab & Sorafenib in Advanced Hepatocellular (Liver) Carcinoma (HCC)” Abstracts: https://iplanner.asco.org/am2015/AM2015.aspx (pub. 5-13-15 5pmET)
Aug26: CHI’s 10th Annual Immunotherapy & Vaccine Summit (IMVACS), Boston http://tinyurl.com/lfdoksl … 9-9:30 Jeff T. Hutchins (VP/Preclin-Res.): “Expansion and Activation of T Cells via the Targeting of the Immunosuppressive Ligand PS: Combination Strategy with Conventional, Targeted, and Checkpoint Inhibitor Therapy”
Bavi's ace in the hole compared to other IO therapy, only Bavi is effective against PD-l and PD-L1 negative tumors. So the patients that would not respond that have negative PD-1/PD-LI are all ours if Bavi's confirms it is effective.
Should Bavi MOS be equal to other IO treatment, due to the side effects Bavi wins.
President & CEO of Nilogen Oncosystems [=Moffit Startup: http://otmc.moffitt.org/startups.aspx ]. "It is an exciting time for the field of immunotherapy and the data we have been generating support that bavituximab has the potential to activate a tumor specific immune response in patients with PD-L1 negative tumors that generally do not respond as well to PD-1 or PD-L1 inhibitors."
Should a patient as many do only tolerate a single dose of Obdiva, those patients should be given Bavi.
Then of course the combination of the two could become the SOC.
So Doce. future depends on the Sunrise results as well.
ASCO’15(May30-Jun2): PPHM’s 3Abstracts & May31/6pmCT I-O Roundtable Webcast - 7 I-O KOL’s on panel, “Raising the Immuno-Oncology Bar: The Next Wave of Immune Modulating Checkpoint Inhibitors"…
May29-Jun2: ASCO Annual Meeting 2015, Chicago http://am.asco.org Abstracts: https://iplanner.asco.org/am2015/AM2015.aspx (pub. 5-13-15 5pmET) • #3059/Sat-May30/8-11:30am, Track: Dev. Therapeutics & Translational Res. - “PS Targeting Antibody in Combination with Anti-PD-1 Antibody Treatment Activates Infiltrating T lymphocytes of the Spleen & Tumor Microenvironment in Pre-Clinical Models of Melanoma & Breast Cancer” - Xianming Huang, PhD (UTSW-MC/Dallas, Brekken Lab) • #3060/Sat-May30/8-11:30am, Track: Dev. Therapeutics & Translational Res. - “Activation of CD8+ Tumor Infiltrating Lymphocytes by Bavituximab in a 3D ex vivo System of Lung Cancer Patients” - Soner Altiok, MD, PhD (H. Lee Moffitt CCC & Res. Institute, Tampa) • #4109/Mon-June1/8:11:30am, Track: Gastrointestinal (NonColorectal) Cancer - “A Phase I/II Study of Bavituximab & Sorafenib in Advanced Hepatocellular Carcinoma (HCC)” - Adam Yopp, MD (UTSW-MC/Dallas) “In addition, Peregrine will be hosting ASCO conf. attendees at Booth #22107” http://ir.peregrineinc.com/releasedetail.cfm?ReleaseID=913039
= = = = = = = = = = = = 5-27-15/PR: Peregrine Pharmaceuticals Announces Webcast of Immunotherapy Roundtable at ASCO Annual Meeting • Immunotherapy Thought Leaders to Discuss Next Wave of Therapies Aimed at Increasing the Number of Patients That Respond to Immuno-Oncology Combination Therapies http://ir.peregrineinc.com/releasedetail.cfm?ReleaseID=915098 TUSTIN, May 27, 2015: Peregrine Pharmaceuticals (Nasdaq:PPHM, PPHMP), a biopharmaceutical company focused on advancing bavituximab, a novel immuno-oncology (I-O) agent in Phase III development for the treatment of lung cancer, invites investors and the general public to listen to a webcast of its roundtable discussion in conjunction with the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting [ http://am.asco.org ]. This roundtable is comprised of key opinion leaders in the field of Immunotherapy who will discuss novel I-O combination therapies that may improve patient outcomes.
Title: "Raising the Immuno-Oncology Bar: The Next Wave of Immune Modulating Checkpoint Inhibitors" Date/Time: Sunday, May 31, 2015 from 6:00-7:00pm CT
The event is being hosted by Peregrine Pharmaceuticals and will be webcast live and archived for 60 days. The event may be accessed from the home page of Peregrine Pharmaceuticals' website at http://www.peregrineinc.com . For the live event, listeners are encouraged to login 5-10 minutes ahead of the scheduled start in order to verify system requirements and complete registration.
Lori Kunkel, MD will moderate this event. Dr. Kunkel serves on the Board of Directors of Loxo Oncology[ http://www.loxooncology.com ], where she held the position of Acting Chief Medical Officer. Previously, Dr. Kunkel was Chief Medical Officer at Pharmacyclics and Proteolix and has also held senior roles at ACT Therapeutics, Syndax, Xencor, and Genitope. Dr. Kunkel received her MD from the Univ. of Southern California and her BA degree from the Univ. of California San Diego.
Kathy D. Miller, MD, Ballve Lantero Scholar in Oncology, Professor, Dept of Medicine, Co-Director, Simon Cancer Center Breast Cancer Program, Indiana University School of Medicine, Indianapolis, IN [ http://www.bcrfcure.org/researchers/kathy-d-miller ]
About Peregrine Pharmaceuticals, Inc. Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a pipeline of novel drug candidates in clinical trials for the treatment and diagnosis of cancer. The company's lead immunotherapy candidate, bavituximab is in Phase III development for the treatment of second-line non-small lung cancer (the "SUNRISE trial") along with several investigator-sponsored trials evaluating other treatment combinations and additional oncology indications. The company is also advancing a molecular imaging agent, 124I-PGN650, in an exploratory clinical trial for the imaging of multiple solid tumor types. Peregrine also has in-house cGMP manufacturing capabilities through its wholly-owned subsidiary Avid Bioservices, Inc. ( http://www.avidbio.com ), which provides development and biomanufacturing services for both Peregrine and third-party customers. Additional information about Peregrine can be found at http://www.peregrineinc.com . CONTACT: Christopher Keenan, Peregrine Pharmaceuticals, Inc., 800-987-8256, info@peregrineinc.com
= = = = = = = = = = = = = SCIENCE:"Evolution has favored pathogenesis that resembles apoptosis." Dr. Judah Folkman: ”This [Thorpe’s VTA research] is very promising and very elegant work... The whole goal is really 2-part, reducing the harsh side effects of cancer treatment, and reducing the chance that some cancer cells will evade treatment. That would be a big step in the next decade, and anti-vascular therapy will play a major role." (’97 & ’02 http://tinyurl.com/k5qe96g & http://tinyurl.com/n6vh9hp ) Peregrine's Bavituximab Clinical Trials website: http://PeregrineTrials.com Bavituximab MOA & Clinical Data: http://www.peregrineinc.com/pipeline/bavituximab-oncology.html ...Bavi Publications: http://www.peregrineinc.com/publications/publications.html ...Bavi Posters & Presentations: http://www.peregrineinc.com/publications/posters-and-presentations.html Bavi MOA: Video (3:34) added ~3-2014 http://vimeo.com/87116642 "Bavituximab: A Novel Immunotherapy Candidate Targeting an Upstream Immune Checkpoint to Fight Cancer" Bavi MOA: Video (1:33) on Bavi’s Immunotherapeutic MOA added to Youtube on 3-27-14 https://www.youtube.com/watch?v=Esewl35JD8s BAVI MOA 5-21-15: NYAS: Emerging Approaches to Cancer Immunotherapy, NYC http://tinyurl.com/lfdoksl …3:10pm: Dr. Rolf Brekken, “Lifting the Veil of Immune Suppression and Inducing Immune Activation through Antibody-mediated Blockade of Phosphatidylserine Signaling” BAVI MOA 3-25-15: PPHM/VP Dr. Jeff Hutchins’ presentation at "Immune Checkpoint Inhibitors Conf.", Boston - PDF(34 Slides): http://tinyurl.com/ooxkhq7 BAVI MOA 2-9-15: PPHM/VP Dr. Bruce Freimark’s presentation at KEYSTONE "Tumor Immunology Meeting", Banff/CN – PR & Slides: http://tinyurl.com/q6cx4w6 BAVI MOA 12-12-14 San Antomio Breast Cancer Symposium, Dr. Bruce Freimark, Bavi+anti-PD-1 vs. Breast Cancer http://tinyurl.com/p5ng6vs BAVI MOA 11-2014 SITC’14: 3 posters on preclin. Bavi+aCTLA4/aPD1 combo data (Hutchins Freimark Brekken Huang etal) http://tinyurl.com/pchzr6h BAVI MOA 8-28-14: Italy’s Dr. Federico Cappuzzo, Bavi/NSCLC profile article (DovePress OpenAccess, 7pgs) - http://tinyurl.com/n3oa7bc BAVI MOA 8-11-14: PPHM/VP Dr. Jeff Hutchins’ presentation at ImVacS "Immunotherapies & Vaccine Summit", Boston - PR: http://tinyurl.com/lpjy3u7 ; PDF(31 Slides): http://tinyurl.com/oueldme ...MLV’s Dr. George Zavoico’s 8-27-14 report on Dr. Jeff Hutchins’ 8-11-14 ImVacS/Boston Bavi MOA presentation: http://tinyurl.com/l3tw63c BAVI MOA 5-28-14: Dr. Rolf Brekken’s 47min CRI “Cancer Immunotherapy” webinar about Bavituximab as an Upstream/Global Immune Checkpoint Inhibitor – REPLAY: http://tinyurl.com/lxgftyx . . .CRI=Cancer Research Institute (NYC – Supported by BMS): http://www.cancerresearch.org - Facebook: http://tinyurl.com/pbmhb2z , https://twitter.com/CancerResearch . . .CRI launches “Answer to Cancer” (cancer immunotherapy) website http://www.theanswertocancer.org . . .8-12-14: CRI adds Youtube links to the 5-28-14 CRI Immunotherapy webinar, incl. Dr. Brekken's talk "about Bavi and how it works against lung, liver, and other kinds of cancers" http://tinyurl.com/ps5h6h8 BAVI MOA 3-25-14: Dr. Rolf Brekken’s 40min talk at NYAS Lung Cancer Symposium http://tinyurl.com/lq9stnk (45 Slides) . . .Dr.Brekken’s talk: “Antibody-mediated Inhibition of PS - A Novel Strategy for Immune Checkpoint Blockade” (the 5 speakers: Jessica Donington, Roy Herbst, Balazs Halmos, Suresh Ramalingam, Rolf Brekken) 12-10-13: With recent scientific insights highlighting bavi’s immunostimulatory moa, these additions to PPHM’s SAB: Dimitry Gabrilovich, Scott Antonia, David Carbone**, Hakan Mellstedt http://tinyurl.com/mw776mk ......**A/o 9-2014, Dr. David Carbone (PPHM SAB/KOL) is President-Elect of IASLC https://www.iaslc.org/about-us/board BAVI MOA: 12-2013 Bavi’s Immunotherapeutic MOA overviewed by UTSW’s Brekken/Huang in Pan European Networks Jrnl. http://tinyurl.com/lnb46pq BAVI MOA 11-9-13: Annual SITC (WashDC) – 2 posters about Bavi’s Immunostimulatory MOA http://tinyurl.com/mjaweu5 ...“We are actively working towards initiating a clinical trial in the coming months to further investigate the potential synergistic effects of bavituximab and an approved [anti-CTLA-4] immunotherapy in patients with Melanoma." 10-28-13 IASLC/Sydney: “Immune Checkpoints in the Tumor Environment: Novel Targets & the Clinical Promise of Combined Immunotherapies” http://tinyurl.com/mjaweu5 …Symposium speakers: Scott J. Antonia/MD-PhD(H.Lee Moffitt CC), Dmitry I. Gabrilovich/MD-PhD(Wistar Inst), Rolf A. Brekken/PhD(UTSW), David E. Gerber/MD(UTSW) BAVI MOA: 8-19-13 Data Supporting Bavituximab’s Immunotherapy MOA Published in “Cancer Immunology Research” (AACR) - http://tinyurl.com/mhjftka (PDF) …“PS-Targeting Antibody Induces M1 Macrophage Polarization & Promotes Myeloid-Derived Suppressor Cell Differentiation” (Thorpe etal) BAVI MOA: 8-13-13 PPHM/VP Dr. Jeff Hutchins’ Presentation on the Downstream Immunostimulatory Effects/Moa of PS-targeting antibodies (like Bavi) at CHI’s “Immunotherapies Congress”/Boston http://tinyurl.com/m6h2tvt BAVI MOA: 10-12-12 NMB article on how Bavi "Induces Innate & Specific Anti-tumor Responses" http://tinyurl.com/cw9odb8 BAVI MOA: 5-1-12 Dr. Phil Thorpe's 46min talk at NYAS PS-Targeting Symposium http://tinyurl.com/9792gl5 . . .Symposium title: "Phosphatidylserine (PS) Asymmetry - Therapeutic Apps. in Cancer & Infectious Disease Symposium" . . .Replays of 5 speakers: Alan Schroit, Chris Reutlingsperger, David Ucker, Ari Helenius, Philip Thorpe